Health benefit plans; requiring coverage for certain prescription. Effective date.
Summary
SB 176 creates a new section of Oklahoma insurance law requiring certain health benefit plans that cover contraceptive drugs to allow larger fills of those prescriptions. Specifically, when a covered enrollee first obtains a contraceptive drug, the plan must cover up to a three-month supply at one time, and for subsequent fills of the same drug, up to a six-month supply at one time. The bill defines contraceptive drugs as FDA-approved drugs used to prevent pregnancy, including hormonal methods taken orally, transdermally, or intravaginally.
The measure also preserves flexibility for patients and providers. It states that an enrollee may request a smaller supply and that a prescribing provider may prescribe a smaller supply when clinically appropriate. At the same time, the bill expressly says it does not require coverage for medications that could be used to terminate an existing pregnancy, limiting the scope of the mandate to contraception rather than abortion-related drugs. The act takes effect November 1, 2025.
Impact
SB 176 amends Oklahoma insurance law by adding Section 6060.3b to Title 36, thereby imposing a new coverage requirement on health benefit plans offered, issued, or renewed on or after the effective date. Plans that already cover contraceptive drugs must now permit larger dispensing quantities, which may affect pharmacy benefit administration, refill timing, and insurer utilization management practices. The bill primarily affects insurers, health benefit plan administrators, pharmacies, prescribing providers, and enrollees who use contraceptive medications.
Sentiment
The bill appears to have received generally favorable support in both chambers, passing committee and floor votes with clear majorities. Senate and House votes show more support than opposition overall, suggesting the measure was broadly acceptable to lawmakers. The absence of committee transcript material limits insight into detailed debate, but the voting history indicates the bill was not highly controversial at the final stages.
Contention
The main point of contention is likely the policy and political sensitivity surrounding contraception coverage and the distinction between contraceptive drugs and medications that could terminate an existing pregnancy. The bill’s explicit exclusion of drugs that could be used to end a pregnancy suggests lawmakers anticipated concern about abortion-related implications. Another possible issue is the mandate’s effect on insurers and pharmacy benefit management, since requiring three-month and six-month fills could alter cost, inventory, and utilization practices, though the recorded votes show these concerns did not prevent passage.